Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Oleclumab - AstraZeneca

X
Drug Profile

Oleclumab - AstraZeneca

Alternative Names: Anti-CD73 MAb; Anti-CD73 monoclonal antibody; MEDI-9447

Latest Information Update: 22 Jun 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator MedImmune
  • Developer AstraZeneca; European Network of Gynaecological Oncological Trial Groups; Jules Bordet Institute; M. D. Anderson Cancer Center; MedImmune; National Cancer Institute (USA)
  • Class Antineoplastics; Immunotherapies; Monoclonal antibodies
  • Mechanism of Action 5-nucleotidase inhibitors; Antibody-dependent cell cytotoxicity; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Non-small cell lung cancer
  • Phase II Breast cancer; Ovarian cancer; Pancreatic cancer; Prostate cancer; Sarcoma
  • Phase I/II Colorectal cancer
  • No development reported Bladder cancer; Solid tumours

Most Recent Events

  • 05 Apr 2024 Pharmacodynamics data from the phase II NeoCOAST trial in Non-small cell lung cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 04 Oct 2023 University Health Network plans a phase II trial for Pancreatic Cancer (IV) in October 2023 (NCT06060405)
  • 18 Jul 2023 MedImmune completes the phase II COAST trial for Non-small cell lung cancer (Combination therapy, Monotherapy, Second line therapy or greater, Late stage disease, Unresectable/Inoperable) in US, Canada, France, Hong Kong, Italy, Poland, Portugal, Spain and Taiwan (IV) (NCT03822351)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top